Trial Profile
An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Liatermin (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors MedGenesis Therapeutix
- 25 Apr 2019 Status changed from recruiting to completed.
- 11 Nov 2013 New trial record